{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=97", "query": { "intervention": "Injectable Placebo", "page": 97 }, "page_size": 10 }, "pagination": { "page": 97, "page_size": 10, "total_count": 4226, "total_pages": 423, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=98&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=96&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T00:29:56.828Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01644175", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2012-07", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-11-10T00:29:56.828Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644175" }, { "nct_id": "NCT01740492", "title": "Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Ketamine 0.15mg/kg", "type": "DRUG" }, { "name": "Ketamine 0.3mg/kg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Rhode Island Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 75, "start_date": "2012-09", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2022-09-07", "last_synced_at": "2026-11-10T00:29:56.828Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01740492" }, { "nct_id": "NCT03694444", "title": "A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gingivitis" ], "interventions": [ { "name": "AMY-101", "type": "DRUG" }, { "name": "Water for injection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amyndas Pharmaceuticals S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 39, "start_date": "2019-07-22", "completion_date": "2020-10-30", "has_results": false, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-11-10T00:29:56.828Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03694444" }, { "nct_id": "NCT02808975", "title": "Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hidradenitis Suppurativa (HS)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 206, "start_date": "2016-07-18", "completion_date": "2019-10-16", "has_results": true, "last_update_posted_date": "2020-05-14", "last_synced_at": "2026-11-10T00:29:56.828Z", "location_count": 9, "location_summary": "Beverly Hills, California • Encino, California • Irvine, California + 6 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02808975" }, { "nct_id": "NCT04542681", "title": "MANP in African Americans With Hypertension", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypertension, Resistant to Conventional Therapy" ], "interventions": [ { "name": "Placebo - 1st Cycle", "type": "DRUG" }, { "name": "MANP - 1st Cycle", "type": "DRUG" }, { "name": "MANP - 2nd Cycle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "20 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2018-05-01", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2023-03-09", "last_synced_at": "2026-11-10T00:29:56.828Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04542681" }, { "nct_id": "NCT03802630", "title": "Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Branch Retinal Vein Occlusion" ], "interventions": [ { "name": "Brolucizumab 6 mg", "type": "DRUG" }, { "name": "Aflibercept 2 mg", "type": "DRUG" }, { "name": "Sham injection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2019-07-02", "completion_date": "2021-07-26", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-11-10T00:29:56.828Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Mountain View", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03802630" }, { "nct_id": "NCT03203330", "title": "A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Degenerative Osteoarthritis" ], "interventions": [ { "name": "TG-C", "type": "BIOLOGICAL" }, { "name": "Placebo Control", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kolon TissueGene, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 535, "start_date": "2018-10-30", "completion_date": "2026-08-18", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-10T00:29:56.828Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Apple Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03203330" }, { "nct_id": "NCT01791153", "title": "An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Giant Cell Arteritis" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tocilizumab Placebo", "type": "DRUG" }, { "name": "Prednisone Placebo", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 251, "start_date": "2013-07-22", "completion_date": "2018-06-04", "has_results": true, "last_update_posted_date": "2020-02-06", "last_synced_at": "2026-11-10T00:29:56.828Z", "location_count": 14, "location_summary": "Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Paducah", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01791153" }, { "nct_id": "NCT04426500", "title": "Use of Perioperative Pain Blocks In Urological Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain, Postoperative", "Nerve Block", "Robotic Surgical Procedures" ], "interventions": [ { "name": "Bupivacain", "type": "DRUG" }, { "name": "Ultrasound-guided transversus abdominus plane block", "type": "DRUG" }, { "name": "Laparoscopic-guided transversus abdominus plane block", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2019-11-11", "completion_date": "2021-02-13", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-11-10T00:29:56.828Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04426500" }, { "nct_id": "NCT01490450", "title": "Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Psoriatic" ], "interventions": [ { "name": "Placebo matching BMS-945429", "type": "BIOLOGICAL" }, { "name": "BMS-945429", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2011-12", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-11-10T00:29:56.828Z", "location_count": 8, "location_summary": "San Diego, California • Denver, Colorado • Trumbull, Connecticut + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Trumbull", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490450" } ] }